A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Clinical trial NCT00834093 · COMPLETED

Trial details

NCT number: NCT00834093
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Nasopharyngeal Carcinoma

Start date: 2009-04-01
Primary completion: 2012-03-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.